GPP
KNSA icon

Great Point Partners’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Great Point Partners’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,204,028
Closed -$11.7M – 44
2022
Q2 		$11.7M Buy
1,204,028
+85,961
+8% +$802K 2.8% 16
2022
Q1 		$11.1M Buy
1,118,067
+581,329
+108% +$6.16M 2.69% 17
2021
Q4 		$6.32M Buy
536,738
+56,738
+12% +$697K 1.4% 26
2021
Q3 		$5.47M Buy
+480,000
New +$6.25M 1.27% 30

Other funds holding KNSA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Great Point Partners's KNSA Position: Q3 2022 in Review

Great Point Partners sold out of Kiniksa Pharmaceuticals (KNSA) in Q3 2022, closing a stake of 1,204,028 shares — an estimated $11.7M sold.

Great Point Partners first reported a position in KNSA in Q3 2021 and held it in 4 quarters. The position peaked at $11.7M in Q2 2022. 104 funds tracked by Wall St. Rank hold KNSA as of Q3 2022.

  • Great Point Partners reported no remaining Kiniksa Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Great Point Partners sold 1,204,028 Kiniksa Pharmaceuticals shares in Q3 2022, an estimated $11.7M.
  • Great Point Partners first reported a position in Kiniksa Pharmaceuticals in Q3 2021 and held it in 4 quarters.
  • Great Point Partners's Kiniksa Pharmaceuticals position peaked at $11.7M in Q2 2022.
  • 104 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q3 2022.

Based on Great Point Partners's 13F filing for Q3 2022, filed 14 Nov 2022.